NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
- Mechanism
- Curator reviewed
NXN-188 is a first-in-class, dual-action, small molecule that is being developed for the treatment of acute migraine and which incorporates both 5-HT agonism (the mechanism of action of triptans, the current standard of care in migraine therapy) and nNOS inhibition. NOS is a validated target for migraine therapy as migraine models indicate that nNOS inhibition can relieve pain. Additionally, nitric oxide induces migraines in migraineurs, while the inhibition of NOS has been demonstrated to relieve migraine pain.
- Primary indication
- Investigated for use/treatment in migraine and cluster headaches.Curator reviewed
- Code names
- NXN-188
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with NXN-188, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account